Patterns of botulinum toxin treatment for spasticity and bleeding complications in patients with thrombotic risk

Toxicon. 2017 Nov:138:188-190. doi: 10.1016/j.toxicon.2017.09.007. Epub 2017 Sep 15.

Abstract

The purpose of this study was to assess the prevalence of compartment syndrome or major bleeding episodes and compare compartment syndrome, patient and intervention characteristics in 110 patients with stroke (treated with Warfarin, new oral anticoagulants, antiplatelet, or no anticoagulants) treated for spasticity in deep leg compartment muscles with botulinum toxin injections [onabotulinumtoxinA (n = 77); incobotulinumtoxinA (n = 33)]. We reviewed 674 injection cycles (range 1-25 cycles per patient) and found no cases of compartment syndrome in any patient groups.

Keywords: Botulinum toxins; Compartment syndrome; Hemorrhage; Muscle spasticity; Stroke.

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / therapeutic use
  • Botulinum Toxins, Type A / adverse effects
  • Botulinum Toxins, Type A / therapeutic use*
  • Compartment Syndromes
  • Female
  • Hemorrhage / epidemiology
  • Humans
  • Leg
  • Male
  • Middle Aged
  • Muscle Spasticity / complications
  • Muscle Spasticity / drug therapy*
  • Muscle, Skeletal / drug effects
  • Neuromuscular Agents / adverse effects
  • Neuromuscular Agents / therapeutic use*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Retrospective Studies
  • Stroke / complications

Substances

  • Anticoagulants
  • Neuromuscular Agents
  • Platelet Aggregation Inhibitors
  • Botulinum Toxins, Type A
  • incobotulinumtoxinA